METRO launches a driver-less route, Houston biotech company raises millions, and more quick innovation news. Courtesy of METRO

So much Houston innovation news — so little time. In order to help keep in touch with all the news happening among startups and technology in Houston, we're hitting the highlights in this innovation news roundup.

If you know of innovation-focused news happening, email me at natalie@innovationmap.com with the details and subscribe to our daily newsletter that sends fresh stories straight to your inboxes every morning.


METRO launches a self-driving shuttle on Texas Southern University's campus

Courtesy of Metro

The first autonomous shuttle in Houston recently had its maiden voyage on Texas Southern University's campus. The route is a one-mile stretch that is called the "Tiger Walk.' The EasyMile shuttle can transport 12 passengers and is operated by First Transit. The project is a pilot program for METRO to see if it has successful applications in other public transportation efforts.

"When passengers board this all electric vehicle they will be riding into the future and experiencing a mode of transportation that in just a few years may become commonplace," says METRO Chair Carrin Patman in a release.

The first phase of the pilot kicked off June 5, as reported in a previous InnovationMap article.

After being deemed a hot tech company by Crunchbase, Data Gumbo grows its C-suite

Courtesy of Data Gumbo

In June, Data Gumbo was named among Crunchbase's top 50 hottest tech companies. The list looked for growing tech startups that have raised between $5 million and $20 million, with a recent round closing in the past six months. The Houston-based company closed its most recent round of $6 million in the spring.

Following the round completion, Data Gumbo's CEO, Andrew Bruce, noted the funds were intended to further develop the company's technology and grow the team. As of last week, Bruce made good on the promise and announced the company's new chief commercial officer, Sergio A. Tuberquia.

"As our new capital is being used to expand our commercial blockchain network, we are also expanding our internal teams to support our rapid global growth," says Bruce in a news release. "With Sergio joining to lead revenue efforts, this will further our company's mission to help oil and gas companies — and ultimately all industries -—realize greater efficiencies and cost savings in the supply chain. Sergio's mix of startup technology and oil and gas industry experience will greatly benefit Data Gumbo and its customers as the industry moves into digital oilfield solutions like blockchain."

Biotech company extends its Series D round to $43 million

Getty Images

Following a $20 million commitment from Sanford Health, Houston-based InGeneron Inc. has extended its Series D round to $43 million. The funds will go toward further developing the company's regenerative medicine and cell therapy. InGeneron currently has a clinical study for rotator cuff recovery.

The investment by South Dakota-based Sanford Health was announced in March, and last month, InGeneron made the call to expand the series.

"Sanford Health's continued support helps advance InGeneron's regenerative cell therapy into the expansive pivotal trial phase, a significant step toward bringing our therapy into the clinic," says Angelo Moesslang, CEO of InGeneron, in a release. "This is an exciting time for the company, as one of the largest health systems in the United States further affirms the potential of adipose-derived regenerative cell therapy, while we diligently work to make it available to patients."

Rice Business Plan winner to ring the Nasdaq bell

Courtesy of Rice University

The company that won the top prize at the Rice Business Plan Competition and walked away with almost $700,000 is claiming another one of its prizes. Vita Inclinata Technologies will ring the opening bell at Nasdaq on July 3.

The company, which created a technology to advance helicopter safety, will be represented by its CEO, Caleb Carr, and Brad Burke, managing director of the Rice Alliance for Technology and Entrepreneurship, and Will Roper, the U.S. Air Force's assistant secretary for acquisition, will also attend. The livestream footage is available online, beginning at 8:30 am central.

Mercury Fund raising money

Texas Money

Getty Images

Crunchbase broke the news that Houston-based Mercury Fund has secured $82 million of its fourth fund, Mercury Fund Ventures IV, that will total $125 million, per a regulatory filing that PE Hub reported on. Mercury Fund refused to comment on the ongoing raise, but intends to release more information following the close, a representative confirmed to InnovationMap.

According to Crunchbase's proprietary data, it's the largest fund to date for the firm. The most recent fund closed in 2014 at $105 million. Mercury Fund specializes in SaaS, cloud, and data science technology, according to its website.

Rice University and Baylor College of Medicine researcher recognized

Courtesy of Rice University

Olga Dudchenko, a genomics researcher at Rice University and Baylor College of Medicine, been named to MIT Technology Review magazine's 2019 list of 35 Innovators Under 35.

Dudchenko, who is completing her postdoctoral fellowship at Rice's Center for Theoretical Biological Physics, has developed a method to sequence and assemble the genome of any organism for less than $1,000. Her process is comparable the that of the Human Genome Project, which cost $3 billion.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Modular nuclear reactor co. NuScale Power moves into Houston market

New to Hou

The nuclear energy renaissance continues in Texas with an announcement by NuScale Power. The Oregon-based provider of proprietary and innovative advanced small modular reactor (SMR) nuclear technology announced in April it would be opening office space in Houston’s CityCentre.

“Opening this space in Houston underscores our commitment to meeting rising energy demand with safe, scalable nuclear technology,” John Hopkins, NuScale president and CEO, said in a news release. “This move expands our presence in a key market for partners, prospective customers, and stakeholders in addition to positioning us for the future as we focus on the near-term deployment of our industry-leading technology. Texas is leading the way in embracing advanced nuclear for grid resilience and industrial decarbonization, and we’re proud to expand our footprint and capabilities in this important region.”

Interest in nuclear power has been growing in recent years thanks to tensions with oil-rich nations, concerns about man-made climate change from fossil fuels, and the rapidly increasing power needs of data centers. Both Dow and Texas A&M University have announced expanded nuclear power projects in the last year, with an eye of changing the face of Texas’s energy industry through smaller, safer fission reactors.

Enter NuScale, founded in 2007 from technology developed at the University of Oregon. Their modular SMR technology generates 77 megawatts and is one of the only small modular reactors (SMR) to receive design approval from the U.S. Nuclear Regulatory Commission (NRC). These advances have led to runaway success for NuScale, whose stock has risen by more than 1,670 percent since the start of 2024.

The new operations campus in CityCentre is expected to facilitate the movement, installation and coordination of NuScale technology into the various energy systems. Typically, SMRs are used for off-grid installations, desalination operations, mining facilities and similar areas that lack infrastructure. However, the modularity means that they can be easily deployed to a variety of areas.

It comes none too soon. ERCOT projects that Texas data centers alone will require 77,965 megawatts by 2030.

---

This article first appeared on EnergyCapitalHTX.com.

Pharma giant considers Houston for $1 billion manufacturing campus

in the works

Another pharmaceutical giant is considering Houston’s Generation Park for a manufacturing hub.

According to a recent filing with the Texas Jobs, Energy, Technology and Innovation (JETI) program, Bristol Myers Squibb Co. is considering the northeast Houston management district for a new $1 billion multi-modal pharmaceutical manufacturing campus.

If approved, the campus, known as Project Argonaut, could create 489 jobs in Texas by 2031. Jobs would include operations technicians, engineering roles, administrative and management roles, production specialists, maintenance support, and quality control/assurance. The company predicts annual average wages for these positions to be around $96,000, according to the filing.

The project currently includes the 600,000-square-foot facility, but according to the filing, Bristol Myers Squibb “envisions this site growing in scale and capability well beyond its opening configuration."

The Texas JETI program offers companies temporary school property tax limitations in exchange for major capital investment and job creation. E.R. Squibb & Sons LLC applied for a 10-year tax abatement agreement in the Sheldon Independent School District.

The agreement promises a $ 1 billion investment. Construction would begin in 2027 and wrap in 2029.

“The proposed project reflects [Bristol Myers Squibb Co.’s] enduring commitment to bringing innovative medicines to patients and ensuring the long-term supply reliability they depend on,” the filing says. “The proposed project is purpose-built to support and manufacture medicines spanning multiple therapeutic areas and modalities, positioning the site as a long-term launch and commercial campus for decades to come. These medicines will provide therapies to the [Bristol Myers Squibb Co.’s] patients located in markets both nationally and internationally.”

The Fortune 100 company is considering 16 other cities for the new manufacturing facility in the Central and Eastern markets in the U.S. According to the Houston Chronicle, Bristol Myers Squibb Co is still in the “evaluation process” for its potential manufacturing site.

Last fall, Eli Lilly and Co. selected Generation Park for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

Houston health tech co. lands NIH grant for AI cancer prediction tool

fresh funding

Houston-based CellChorus and Stanford Medicine were recently awarded a Phase I Small Business Innovation Research grant for the company's AI platform to test how certain cancer patients will respond to therapies.

The funding comes from the National Cancer Institute of the National Institutes of Health. According to a filing, the grant totaled just under $400,000.

CellChorus, which spun out from the University of Houston’s Technology Bridge, has developed TIMING (Time-lapse Imaging Microscopy In Nanowell Grids), which analyzes the behavior of thousands of individual immune cells over time and can identify early indicators of treatment success or failure.

The company will work with Stanford's Dr. David Miklos and Dr. Saurabh Dahiya, who have built the Bone Marrow Transplantation and Cell Therapy Biobank. The biobank manages and stores biological samples from patients treated at their clinic and in clinical trials.

"Predicting which patients will achieve durable responses after CAR-T therapy remains one of the most important challenges in the field,” Miklos said in a news release. “We aim to uncover functional cellular signatures that can guide treatment decisions and improve patient outcomes.”

The project will specifically profile cells from patients with relapsed/refractory large B-cell lymphoma (r/rLBCL). According to CellChorus, only about half of r/rLBCL patients who receive CAR-T therapy "achieve a durable, long-term remission." Others do not respond to therapy or experience relapse.

“The sooner we know whether a cancer therapy is working, the better. To maximize patient benefit, we need technology that can provide a robust and early prediction of response to therapy. The technology needs to be scalable, cost-efficient, and capable of rapid turnaround times,” Rebecca Berdeaux, chief scientific officer of CellChorus, added in the release. “We are excited to work with Drs. David Miklos and Saurabh Dahiya and their colleagues on this very important project.”

CellChorus has previously received SBIR grants from federal agencies, including a $2.5 million award in 2024 from its National Center for Advancing Translational Sciences (NCATS) and a $2.3 million SBIR Fast-Track award from the National Institute of General Medical Sciences in 2023.